Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | RXRG | P48443 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401385 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2RXRARXRBPPARGRXRG | |
| SCHEMBL25238832 | 0.96 | SMN1; SMN2 (0.38) | SMN1; SMN2RXRARXRBPPARGRXRG | |
| SCHEMBL20978166 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2RXRARXRBPPARGRXRG | |
| SCHEMBL23860824 | 0.79 | NOS3 (0.46) | SMN1; SMN2ACHEMAPK1BCHECHRM1 | |
| SCHEMBL30133422 | 0.79 | NOS3 (0.46) | SMN1; SMN2ACHEMAPK1BCHECHRM1 | |
| SCHEMBL30496070 | 0.75 | ACHE (0.39) | SMN1; SMN2ACHENLRP3BCHECHRM1 | |
| SCHEMBL30667978 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2GLAHTTMAPK1NSD2 | |
| SCHEMBL25433645 | 0.75 | ACHE (0.39) | SMN1; SMN2ACHENLRP3BCHECHRM1 | |
| SCHEMBL26684739 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2GLAHTTMAPK1NSD2 | |
| SCHEMBL25052864 | 0.74 | SMN1; SMN2 (0.36) | SMN1; SMN2RXRARXRBPPARGRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4674841-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-118973578-A | Pharmaceutical compounds | 杜克街生物有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4444305-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023156386-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156386-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2023-08-24 | — | — | WO | disclosed |
| US-20160194320-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194320-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2016-07-07 | — | — | US | disclosed |
| US-9266855-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-02-23 | — | — | US | disclosed |
| US-9266855-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-02-23 | — | — | US | disclosed |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054874-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012041814-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194320-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | SMN1; SMN2 3211/4885RXRA 4212/4885RXRB 4007/4885 |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | SMN1; SMN2 3748/4885RXRA 1035/4885RXRB 1920/4885 |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | SMN1; SMN2 3211/4885RXRA 4212/4885RXRB 4007/4885 |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | SMN1; SMN2 3211/4885RXRA 4212/4885RXRB 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.